Notably, TP53, highly mutated in ESCC7, was the top-ranked mutation in ESCC progression, and was prominent in the younger male ESCC patients (Fisher’s exact test, p = 0.044, 65.8%) in our cohort (Supplementary Fig. 4h). The gene discussed is TP53; the disease is esophageal squamous cell carcinoma.